Castle Rock Wealth Management LLC Has $1.88 Million Stock Holdings in Johnson & Johnson (NYSE:JNJ)

Castle Rock Wealth Management LLC increased its position in shares of Johnson & Johnson (NYSE:JNJ) by 1.1% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 11,526 shares of the company’s stock after acquiring an additional 124 shares during the period. Castle Rock Wealth Management LLC’s holdings in Johnson & Johnson were worth $1,877,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also made changes to their positions in JNJ. GW&K Investment Management LLC acquired a new stake in Johnson & Johnson in the fourth quarter valued at approximately $35,000. Dark Forest Capital Management LP boosted its position in Johnson & Johnson by 1,044.4% in the fourth quarter. Dark Forest Capital Management LP now owns 206 shares of the company’s stock valued at $36,000 after buying an additional 188 shares in the last quarter. Atlantic Private Wealth LLC acquired a new stake in Johnson & Johnson in the first quarter valued at approximately $32,000. Ruedi Wealth Management Inc. acquired a new stake in Johnson & Johnson in the fourth quarter valued at approximately $42,000. Finally, Kepos Capital LP acquired a new stake in Johnson & Johnson in the fourth quarter valued at approximately $45,000. Institutional investors and hedge funds own 68.40% of the company’s stock.

Johnson & Johnson Stock Up 0.6 %

Shares of NYSE JNJ opened at $162.41 on Tuesday. The stock has a market capitalization of $422.10 billion, a P/E ratio of 32.88, a P/E/G ratio of 3.26 and a beta of 0.54. The company has a 50-day moving average price of $166.21 and a 200-day moving average price of $161.83. Johnson & Johnson has a 1 year low of $150.11 and a 1 year high of $181.04. The company has a debt-to-equity ratio of 0.44, a current ratio of 1.12 and a quick ratio of 0.88.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings data on Thursday, July 20th. The company reported $2.80 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.62 by $0.18. The firm had revenue of $25.53 billion during the quarter, compared to analysts’ expectations of $24.63 billion. Johnson & Johnson had a net margin of 13.35% and a return on equity of 36.72%. The business’s revenue was up 6.3% on a year-over-year basis. During the same period last year, the company earned $2.59 earnings per share. On average, equities research analysts forecast that Johnson & Johnson will post 10.03 EPS for the current fiscal year.

Johnson & Johnson Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Thursday, September 7th. Investors of record on Monday, August 28th were issued a dividend of $1.19 per share. This represents a $4.76 annualized dividend and a yield of 2.93%. The ex-dividend date was Friday, August 25th. Johnson & Johnson’s dividend payout ratio (DPR) is presently 96.36%.

Analysts Set New Price Targets

A number of brokerages have recently commented on JNJ. Atlantic Securities lifted their price target on shares of Johnson & Johnson from $167.00 to $170.00 and gave the stock a “neutral” rating in a report on Friday, August 4th. Stifel Nicolaus lifted their price target on shares of Johnson & Johnson from $165.00 to $175.00 in a report on Friday, July 21st. Wells Fargo & Company cut their price target on shares of Johnson & Johnson from $195.00 to $186.00 and set an “overweight” rating on the stock in a report on Thursday, August 31st. Cantor Fitzgerald reiterated an “overweight” rating and set a $215.00 price target on shares of Johnson & Johnson in a report on Monday. Finally, Barclays lowered their target price on shares of Johnson & Johnson from $175.00 to $158.00 and set an “equal weight” rating for the company in a research note on Friday, September 8th. Nine investment analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Hold” and a consensus price target of $170.65.

Insider Buying and Selling

In related news, insider William Hait sold 14,698 shares of the business’s stock in a transaction dated Wednesday, July 26th. The shares were sold at an average price of $172.00, for a total transaction of $2,528,056.00. Following the transaction, the insider now directly owns 87,747 shares in the company, valued at $15,092,484. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. In other Johnson & Johnson news, VP Peter Fasolo sold 20,000 shares of the business’s stock in a transaction dated Tuesday, July 25th. The shares were sold at an average price of $170.32, for a total value of $3,406,400.00. Following the transaction, the vice president now directly owns 102,696 shares in the company, valued at $17,491,182.72. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, insider William Hait sold 14,698 shares of the business’s stock in a transaction dated Wednesday, July 26th. The shares were sold at an average price of $172.00, for a total transaction of $2,528,056.00. Following the completion of the transaction, the insider now owns 87,747 shares in the company, valued at $15,092,484. The disclosure for this sale can be found here. 0.20% of the stock is owned by corporate insiders.

Johnson & Johnson Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment provides skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; NICORETTE smoking cessation products; and PEPCID acid reflux products.